INS and type 2 diabetes mellitus: In particular, a randomized controlled trial (RCT) conducted on patients with type 2 diabetes mellitus (T2DM) showed that TN-based treatments led to a significant reduction in fasting plasma insulin and overall glycemic levels, with a notable correlation between ABA plasma levels and glycemia [3].